Niphon PoungvarinWiyada BhoopatAdulya ViriyavejakulPrakit RodprasertPanya BuranasiriSombut SukondhabhantMichael J. HensleyBrian L. StromMahidol UniversityUniversity of Newcastle, AustraliaUniversity of Pennsylvania, School of Medicine2018-06-142018-06-141987-05-14New England Journal of Medicine. Vol.316, No.20 (1987), 1229-123315334406002847932-s2.0-0023175662https://repository.li.mahidol.ac.th/handle/20.500.14594/15421To evaluate the efficacy of dexamethasone for treatment of primary supratentorial intracerebral hemorrhage, we studied 93 patients 40 to 80 years old, using a double-blind randomized block design. After the subjects were stratified according to their level of consciousness (Glasgow Coma Scale), those with objectively documented primary supratentorial intracerebral hemorrhage were randomly assigned to either dexamethasone or placebo. For ethical reasons, three interim analyses were planned, to permit early termination of the trial if one study group did better than the other. During the third interim analysis, the death rate at the 21st day was identical in the two groups (dexamethasone vs. placebo, 21 of 46 vs. 21 of 47; chi-square = 0.01, P = 0.93). In contrast, the rate of complications (mostly infections and complications of diabetes) was much higher in the dexamethasone group (chi-square = 10.89, P < 0.001), leading to early termination of the study. In the light of the absence of a demonstrable beneficial effect and the presence of a significant harmful effect, current practices of using dexamethasone for treatment of primary supratentorial hemorrhage should be reconsidered. (N Engl J Med 1987; 316:122933.) DEXAMETHASONE is known to be effective in reducing vasogenic cerebral edema associated with either primary and metastatic brain tumor or brain abscess. 1,2 Early enthusiastic reports of benefits obtained with cortisone therapy for “apoplectic stroke“3 and dexamethasone for acute stroke 4 led to the use of corticosteroids to treat or prevent acute cerebral edema accompanying stroke. Later, however, randomized clinical trials found no benefit from corticosteroids in the treatment of cerebral infarction. 5 6 7 8 9 However, a similar controversy over the benefit of corticosteroids in treating primary supratentorial intracerebral hemorrhage remains unresolved. Theoretically, the short-term use of dexamethasone is justified because it lessens the damaging. © 1987, Massachusetts Medical Society. All rights reserved.Mahidol UniversityMedicineArticleSCOPUS10.1056/NEJM198705143162001